Early is Good (EIG), a leading diagnostic company specialising in multi-omic technology, announces a collaboration with Mayo Clinic to develop an advanced liquid biopsy test tailored for men with advanced prostate cancer.
This innovative partnership aims to address the current limitations in treatment strategies for metastatic castration-resistant prostate cancer (mCRPC) by leveraging comprehensive multi-omic analysis, potentially revolutionising patient care and outcomes. The proposed liquid biopsy test, if successful, could be integrated into EIG's proprietary Multi-omic Integration Platform, offering personalised care plans based on individual cancer biology.
Dr. Thakshila Liyanage, CEO of Early is Good, emphasises the potential impact on patient outcomes, highlighting the urgent need for more effective diagnostic approaches in advanced prostate cancer. Dr. Eric Kim, VP of Clinical Sciences at Early is Good, underscores the collaborative effort's significance in combining Mayo Clinic's clinical expertise with EIG's innovative technology, with future collaborations aimed at expanding the application to various cancers and disease stages.
Click here to read the original news story.